TY - JOUR
T1 - Evidence-based clinical practice guidelines for inflammatory bowel disease
AU - Matsuoka, Katsuyoshi
AU - Kobayashi, Taku
AU - Ueno, Fumiaki
AU - Matsui, Toshiyuki
AU - Hirai, Fumihito
AU - Inoue, Nagamu
AU - Kato, Jun
AU - Kobayashi, Kenji
AU - Kobayashi, Kiyonori
AU - Koganei, Kazutaka
AU - Kunisaki, Reiko
AU - Motoya, Satoshi
AU - Nagahori, Masakazu
AU - Nakase, Hiroshi
AU - Omata, Fumio
AU - Saruta, Masayuki
AU - Watanabe, Toshiaki
AU - Tanaka, Toshiaki
AU - Kanai, Takanori
AU - Noguchi, Yoshinori
AU - Takahashi, Ken ichi
AU - Watanabe, Kenji
AU - Hibi, Toshifumi
AU - Suzuki, Yasuo
AU - Watanabe, Mamoru
AU - Sugano, Kentaro
AU - Shimosegawa, Tooru
N1 - Funding Information:
The members of the Guidelines Committee are listed in the Appendix. Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors have received individually any income, honoraria or any other types of remuneration; Abbvie Inc., EA Pharma Co., Ltd., Eisai Co., Ltd., IGAKU-SHOIN Ltd, Yakult Honsha Co., Ltd, Mitsubishi Tanabe Pharma Corporation; and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation); Asahi Kasei Medical Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Abbvie Inc., EA Pharma Co., Ltd., Eisai Co., Ltd., Eidia Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Biofermin Seiyaku Co., Ltd., Pfizer Inc. Bristol-Myers Squibb Company, Merck Serono Co., Ltd. Mochida Pharmaceutical Co., Ltd. Yakult Honsha Co., Ltd., Janssen Pharmaceutical K.K.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn’s disease (CD) in Japanese. A total of 59 clinical questions for 9 categories (1. clinical features of IBD; 2. diagnosis; 3. general consideration in treatment; 4. therapeutic interventions for IBD; 5. treatment of UC; 6. treatment of CD; 7. extraintestinal complications; 8. cancer surveillance; 9. IBD in special situation) were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases. The guidelines were developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Recommendations were made using Delphi rounds. This English version was produced and edited based on the existing updated guidelines in Japanese.
AB - Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn’s disease (CD) in Japanese. A total of 59 clinical questions for 9 categories (1. clinical features of IBD; 2. diagnosis; 3. general consideration in treatment; 4. therapeutic interventions for IBD; 5. treatment of UC; 6. treatment of CD; 7. extraintestinal complications; 8. cancer surveillance; 9. IBD in special situation) were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases. The guidelines were developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Recommendations were made using Delphi rounds. This English version was produced and edited based on the existing updated guidelines in Japanese.
KW - Consensus
KW - Crohn’s disease
KW - Evidence
KW - Guidelines
KW - Inflammatory bowel disease
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85041923106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041923106&partnerID=8YFLogxK
U2 - 10.1007/s00535-018-1439-1
DO - 10.1007/s00535-018-1439-1
M3 - Review article
C2 - 29429045
AN - SCOPUS:85041923106
SN - 0944-1174
VL - 53
SP - 305
EP - 353
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 3
ER -